Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reaffirmed at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $50.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 278.50% from the stock’s previous close.

Several other equities research analysts also recently issued reports on DAWN. JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a report on Monday. Needham & Company LLC upped their price objective on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday. The Goldman Sachs Group dropped their price target on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Piper Sandler reaffirmed an “overweight” rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Stock Down 13.0 %

NASDAQ DAWN opened at $13.21 on Wednesday. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -5.55 and a beta of -1.48. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $17.85. The business has a 50 day moving average price of $15.23 and a 200-day moving average price of $13.79.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, equities research analysts anticipate that Day One Biopharmaceuticals will post -2.66 earnings per share for the current year.

Insider Activity

In other news, CEO Jeremy Bender sold 7,615 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the transaction, the chief executive officer now directly owns 721,813 shares in the company, valued at approximately $11,007,648.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Jeremy Bender sold 7,615 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $116,128.75. Following the transaction, the chief executive officer now directly owns 721,813 shares in the company, valued at approximately $11,007,648.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel Adam Dubow sold 3,242 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the transaction, the general counsel now owns 16,585 shares in the company, valued at $252,921.25. The disclosure for this sale can be found here. In the last three months, insiders have sold 55,781 shares of company stock worth $883,160. 8.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. lifted its holdings in Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock worth $27,000 after buying an additional 1,262 shares during the period. Quest Partners LLC purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $29,000. Quintet Private Bank Europe S.A. lifted its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after buying an additional 1,000 shares during the period. Amalgamated Bank lifted its holdings in Day One Biopharmaceuticals by 35.7% in the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after buying an additional 2,268 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in Day One Biopharmaceuticals by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock worth $147,000 after buying an additional 2,554 shares during the period. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.